Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients

被引：0
|
作者：
Gevers, T. J. G. [1 ]
Burger, D. [2 ]
Schipper-Reintjes, E. [3 ]
Kooistra, M. P. [3 ]
Richter, C. [1 ]
机构：
[1] Rijnstate Hosp, Dept Infect Dis, Arnhem, Netherlands
[2] RadboudUMC, Dept Pharm, Nijmegen, Netherlands
[3] Rijnstate Hosp, Dept Nephrol, Arnhem, Netherlands
来源：
NETHERLANDS JOURNAL OF MEDICINE | 2016年 / 74卷 / 05期
关键词：
STAGE RENAL-DISEASE; VIRUS-INFECTION; PEGYLATED INTERFERON-ALPHA-2A; TREATMENT-NAIVE; RIBAVIRIN; EFFICACY; SAFETY; PHARMACOKINETICS; METAANALYSIS; IMPAIRMENT;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：225 / 227
页数：3
相关论文
共 50 条
  • [1] Sofosbuvir plus daclatasvir as an alternative for patients on haemodialysis with genotype 2 hepatitis C virus infection
    Llenas-Garcia, Jara
    Padilla, Sergio
    Masia, Mar
    Gutierrez, Felix
    [J]. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2018, 36 (07): : 457 - 457
  • [2] Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients With Chronic Hepatitis C Infection
    Yakoot, Mostafa
    El-Shabrawi, Mortada H.
    AbdElgawad, Manal M.
    Mahfouz, Aml A.
    Helmy, Sherine
    Abdo, Alaa M.
    El-Khayat, Hisham R.
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2018, 67 (01): : 86 - 89
  • [3] Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients
    Abdelaty, Lamiaa N.
    Elnaggar, Ahmed A.
    Said, Amira A.
    Hussein, Raghda R. S.
    [J]. CURRENT DRUG SAFETY, 2020, 15 (01) : 53 - 60
  • [4] Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection
    Elbaz, Tamer
    Abdo, Mahmoud
    Omar, Heba
    Hassan, Essam A.
    Zaghloul, Amr M.
    Abdel-Samiee, Mohamed
    Moustafa, Ahmed
    Qawzae, Abdallah
    Gamil, Mostafa
    Esmat, Gamal
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2019, 91 (02) : 272 - 277
  • [5] Compare the Efficacy of Sofosbuvir Plus Ribavirin Verus Sofosbuvir Plus Daclatasvir in Patients with Chronic C Hepatitis Genotype 2 Infection
    Chang, Kuo-Chin
    Hu, Tsung-Hui
    Chen, Chien Hung
    Wang, Jing-Houng
    [J]. HEPATOLOGY, 2018, 68 : 586A - 586A
  • [6] Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection
    Sundaram, Vinay
    Kowdley, Kris V.
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (01) : 13 - 20
  • [7] Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients
    Huang, Hongfeng
    Tang, Huanna
    Deng, Hao
    Shen, Jia
    Zhou, Qin
    Xie, Wenqing
    Wu, Jianyong
    Chen, Jianghua
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2019, 21 (01)
  • [8] Effect of sofosbuvir plus daclatasvir for treatment of chronic hepatitis C on patients with psoriasis
    Ismail, Waleed A.
    Yousef, Ayman E.
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (08) : 1025 - 1029
  • [9] Efficacy of Low Dose Sofosbuvir and Daclatasvir in Treatment of Chronic Hepatitis C in Patients with End Stage Renal Disease
    Ijaz, Ahmar
    Akram, Mateen
    Anwar, Shahid
    Khan, Azhar Ali
    Saboor, Qazi
    Ibad-ur-Rehman
    [J]. PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2022, 16 (01): : 140 - 142
  • [10] SOFOSBUVIR/ DACLATASVIR AND NOT SOFOSBUVIR/VELPATASVIR RESULTS IN ADVERSE LIPID PROFILE CHANGES IN CHRONIC HEPATITIS C PATIENTS
    Kolhe, Kailash M.
    Ingle, Meghraj
    Pandey, Vikas
    Gattani, Mayur
    Chauhan, Shamsher
    Khairnar, Harshad
    Vishwanathan, Deepti
    Chaudhary, Vipul
    Jadhav, Rahul
    Walke, Swapnil
    Shukla, Akash
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S1321 - S1322
12345